BIOMAT Database Logo BIOMAT Database Logo

A novel indigoid anti-tuberculosis agent. 2014

Larry L Klein, and Valentina Petukhova, and Baojie Wan, and Yuehong Wang, and Bernard D Santasiero, and David C Lankin, and Guido F Pauli, and Scott G Franzblau
Institute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, 833 S. Wood Street, Chicago 60612, USA. Electronic address: llk@uic.edu.

The structure of a novel indigoid component was characterized by X-ray crystallography. This compound exhibited excellent anti-tuberculosis activity against Mycobacterium tuberculosis H37Rv in whole cell culture showing a submicromolar minimum inhibitory concentration (MIC). A synthesis of this molecule was designed and carried out to produce sufficient material for further testing. The in vitro profile, structure, and first synthesis of this indigoid component is reported.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D018360 Crystallography, X-Ray The study of crystal structure using X-RAY DIFFRACTION techniques. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) X-Ray Crystallography,Crystallography, X Ray,Crystallography, Xray,X Ray Crystallography,Xray Crystallography,Crystallographies, X Ray,X Ray Crystallographies

Related Publications

Larry L Klein, and Valentina Petukhova, and Baojie Wan, and Yuehong Wang, and Bernard D Santasiero, and David C Lankin, and Guido F Pauli, and Scott G Franzblau
Streptomycin; a valuable anti-tuberculosis agent.
January 1948, British medical journal,
Larry L Klein, and Valentina Petukhova, and Baojie Wan, and Yuehong Wang, and Bernard D Santasiero, and David C Lankin, and Guido F Pauli, and Scott G Franzblau
Identification of novel anti-tuberculosis agent: An in silico investigation.
October 2022, The Indian journal of tuberculosis,
Larry L Klein, and Valentina Petukhova, and Baojie Wan, and Yuehong Wang, and Bernard D Santasiero, and David C Lankin, and Guido F Pauli, and Scott G Franzblau
Discovery and preclinical evaluations of JBD0131, a novel nitrodihydro-imidazooxazole anti-tuberculosis agent.
September 2022, Bioorganic & medicinal chemistry letters,
Larry L Klein, and Valentina Petukhova, and Baojie Wan, and Yuehong Wang, and Bernard D Santasiero, and David C Lankin, and Guido F Pauli, and Scott G Franzblau
Discovery and preclinical profile of sudapyridine (WX-081), a novel anti-tuberculosis agent.
September 2022, Bioorganic & medicinal chemistry letters,
Larry L Klein, and Valentina Petukhova, and Baojie Wan, and Yuehong Wang, and Bernard D Santasiero, and David C Lankin, and Guido F Pauli, and Scott G Franzblau
Teixobactin: a novel anti-infective agent.
January 2019, Expert review of anti-infective therapy,
Larry L Klein, and Valentina Petukhova, and Baojie Wan, and Yuehong Wang, and Bernard D Santasiero, and David C Lankin, and Guido F Pauli, and Scott G Franzblau
IP6: a novel anti-cancer agent.
January 1997, Life sciences,
Larry L Klein, and Valentina Petukhova, and Baojie Wan, and Yuehong Wang, and Bernard D Santasiero, and David C Lankin, and Guido F Pauli, and Scott G Franzblau
Ethanolamine: A novel anti-aging agent.
January 2016, Molecular & cellular oncology,
Larry L Klein, and Valentina Petukhova, and Baojie Wan, and Yuehong Wang, and Bernard D Santasiero, and David C Lankin, and Guido F Pauli, and Scott G Franzblau
[A novel anti-HIV agent--agenerase].
January 2002, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic],
Larry L Klein, and Valentina Petukhova, and Baojie Wan, and Yuehong Wang, and Bernard D Santasiero, and David C Lankin, and Guido F Pauli, and Scott G Franzblau
Piroxicam, a novel anti-inflammatory agent.
January 1976, Arzneimittel-Forschung,
Larry L Klein, and Valentina Petukhova, and Baojie Wan, and Yuehong Wang, and Bernard D Santasiero, and David C Lankin, and Guido F Pauli, and Scott G Franzblau
AHR-15010--a novel anti-arthritic agent.
August 1990, The Journal of pharmacy and pharmacology,
Copied contents to your clipboard!